Department of Medicine, University of Toronto, Women’s College Hospital, and co-authors have found biologics targeting interleukin (IL)-12, IL-23, or IL-17 were associated with a lower rate of serious infections among older adults with psoriatic disease. These biologics may have important safety benefits for older adults with higher infection risk compared to other existing treatments.
This article was originally published on MedicalXpress.com